Amicus Therapeutics (NASDAQ:FOLD) Insider Ellen Rosenberg Sells 36,000 Shares of Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider Ellen Rosenberg sold 36,000 shares of the stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $10.00, for a total value of $360,000.00. Following the sale, the insider owned 507,710 shares in the company, valued at $5,077,100. The trade was a 6.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Ellen Rosenberg also recently made the following trade(s):

• On Wednesday, November 26th, Ellen Rosenberg sold 23,621 shares of Amicus Therapeutics stock. The shares were sold at an average price of $10.00, for a total value of $236,210.00.

Amicus Therapeutics Price Performance

Shares of NASDAQ FOLD opened at $10.02 on Thursday. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29. The firm has a market capitalization of $3.09 billion, a PE ratio of -83.49 and a beta of 0.66. Amicus Therapeutics, Inc. has a 1-year low of $5.51 and a 1-year high of $10.57. The business’s fifty day moving average price is $8.73 and its two-hundred day moving average price is $7.34.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.12 by $0.05. The business had revenue of $169.06 million during the quarter, compared to analyst estimates of $165.24 million. Amicus Therapeutics had a negative net margin of 6.67% and a negative return on equity of 5.07%. The company’s quarterly revenue was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.10 earnings per share. Amicus Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts expect that Amicus Therapeutics, Inc. will post 0.15 EPS for the current year.

Institutional Trading of Amicus Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in Amicus Therapeutics by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 29,534,029 shares of the biopharmaceutical company’s stock valued at $232,728,000 after buying an additional 126,441 shares during the period. Wellington Management Group LLP increased its stake in shares of Amicus Therapeutics by 2.6% in the first quarter. Wellington Management Group LLP now owns 29,200,617 shares of the biopharmaceutical company’s stock worth $238,277,000 after acquiring an additional 738,623 shares during the last quarter. William Blair Investment Management LLC increased its stake in shares of Amicus Therapeutics by 7.6% in the third quarter. William Blair Investment Management LLC now owns 15,749,240 shares of the biopharmaceutical company’s stock worth $124,104,000 after acquiring an additional 1,107,083 shares during the last quarter. Vestal Point Capital LP raised its holdings in shares of Amicus Therapeutics by 178.4% during the second quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company’s stock worth $68,187,000 after acquiring an additional 7,625,000 shares in the last quarter. Finally, State Street Corp boosted its position in Amicus Therapeutics by 21.5% during the second quarter. State Street Corp now owns 11,568,097 shares of the biopharmaceutical company’s stock valued at $66,285,000 after purchasing an additional 2,049,078 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Zacks Research upgraded Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Needham & Company LLC upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Thursday, September 18th. The Goldman Sachs Group increased their price target on Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Wall Street Zen raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $16.57.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.